BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
The European biotech sector is evolving as it seeks to bridge the gap between academic research and commercial drug development. While Europe possesses world-class science, researchers often lack the entrepreneurial training necessary to navigate funding and business strategy compared to their US counterparts. Industry...
IgA nephropathy has transitioned from a neglected rare disease to a high-priority drug development area, driven by academic innovation and FDA regulatory agility. Seven global drug approvals in five years highlight this shift, with next-generation therapies targeting APRIL, BAF, and CD38 to improve patient outcomes and...
Novartis faces a $40 billion market cap decline following three failed clinical trials, including the high-profile Pelicarcin study, which raises questions about the efficacy of antisense oligonucleotides versus siRNA in cardiovascular disease. While the broader pharmaceutical sector continues to embrace disruptive tec...
Moderna and Merck’s Phase III success with personalized neoantigen vaccines marks a significant shift for mRNA therapies beyond infectious diseases, though questions remain regarding manufacturing burdens and broader clinical applicability in non-melanoma tumors. South Korea’s biotech sector continues to attract Wester...
Biotech venture activity remains robust despite the summer season, with 13 rounds securing $791 million last week, bringing third-quarter totals to $6.5 billion. Key developments include the launch of Cardis, which is developing an oral IGF-1R inhibitor to challenge Amgen’s Tepeza, and the expansion of the "newco" mode...
Argenx’s $2.2 billion acquisition of Forte Biosciences marks a strategic expansion of its immunology pipeline, signaling a growing trend of mid-cap biotechs acting as active acquirers in the industry. Beyond deal-making, the integration of generative AI into biopharma R&D workflows is reshaping the tech stack, with com...
The UK biotech sector faces significant transition following the appointment of a new government and the departure of Science Minister Patrick Vallance, though the selection of John Healey as Chancellor provides some stability for industry stakeholders. Regional economic development remains a strategic focus, with pote...
Novartis’s $1.1 billion acquisition of Myricx signals a strategic pivot toward NMT payloads in antibody-drug conjugates, marking a significant advancement in oncology. Simultaneously, the U.K. life sciences sector faces a regulatory evolution as MHRA CEO Lawrence Tallon advocates for proportionate oversight to accelera...
AbbVie’s $10.9 billion acquisition of Apogee signals a strategic expansion in immunology, leveraging Apogee’s half-life extension technology to improve dosing frequency for atopic dermatitis treatments. Regulatory dynamics at the FDA are shifting as the agency moves toward a reversion to the mean, correcting previous d...
Biotech market activity remains robust, with recent IPOs like Parabilis and Kyverna demonstrating strong aftermarket performance despite broader geopolitical tensions and shifting policy at the Fed. The industry is simultaneously navigating the implications of the Biosecure Act, particularly following the Department of...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
